← Back to Search

Platelet Rich Plasma

Platelet-rich Plasma for Lower Back Pain

Phase 1
Waitlist Available
Led By Matthew Pingree, MD
Research Sponsored by Matthew Pingree
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Low back pain VAS score of greater than or equal to 5 at the clinical visit just prior to the first medial branch nerve block
Positive response, defined according to current clinical standards for the diagnosis of facet-mediated low back pain as greater than or equal to 75% pain improvement (as reported by patient) to diagnostic medial branch nerve blocks, one block with lidocaine and the other with bupivacaine.
Must not have
Redness, swelling, rash or other concerning lesions at the injection site just prior to the procedure
History of hemodynamic instability or inability to maintain stable oncotic pressure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 to day 14
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment for people with lower back arthritis. The treatment uses a special system to concentrate a part of the patient's own blood and inject it into their lower back. The goal is to see if this can help reduce pain and improve healing. The study will monitor patients over time to assess safety and effectiveness.

Who is the study for?
This trial is for adults with significant low back pain from arthritis in the lower spine, confirmed by clinical and imaging tests. Participants must have had a strong positive response to diagnostic nerve blocks. Exclusions include recent illicit drug use, prior lumbar procedures, allergies to local anesthetics, certain medication use including anticoagulants and NSAIDs, pregnancy or breastfeeding, ongoing chemotherapy or opioid use over a set limit.
What is being tested?
The study is testing the Angel Concentrated Platelet Rich Plasma System's safety when used to treat facetogenic low back pain caused by arthritis. The system processes PRP which is then injected into the patient's lower back area affected by arthritis.
What are the potential side effects?
While specific side effects of PRP are not detailed here, common ones may include pain at injection site, infection risk increase due to needle insertion into skin and tissue inflammation as body reacts to treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lower back pain level is 5 or higher on the pain scale.
Select...
I experienced significant pain relief from my lower back pain after two specific nerve block injections.
Select...
I have back pain due to arthritis in my lower spine.
Select...
I have a low back pain score of 5 or more.
Select...
I have back pain confirmed by scans to be due to facet joint problems in the lower spine.
Select...
I experienced a significant pain reduction from nerve block treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have redness, swelling, or a rash at the injection site.
Select...
I have had issues with blood pressure stability or maintaining fluid balance.
Select...
I have not had a fever or signs of infection in the last 24 hours.
Select...
I am currently receiving chemotherapy.
Select...
I have had surgery on my lower back before.
Select...
I take more than 50mg of pain medication daily.
Select...
I've had a back procedure or injection in the last 6 months or a fusion in the lower back.
Select...
I have a history of low platelet counts or my count is below 195,000.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to day 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to day 14 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of adverse device effects
Number of suspected acute adverse reactions to the treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRP Injection ArmExperimental Treatment2 Interventions
The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Platelet Rich Plasma
2016
Completed Phase 4
~1100

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Platelet-Rich Plasma (PRP) therapy is a promising treatment for Lumbar Spondylosis, involving the injection of concentrated platelets from the patient's own blood into the affected area. The platelets release growth factors that promote tissue repair and reduce inflammation, addressing the degenerative changes and inflammation characteristic of Lumbar Spondylosis. This can lead to pain relief and improved function. Other common treatments include physical therapy, which strengthens and stabilizes the spine, and medications like NSAIDs that reduce inflammation and pain. These treatments collectively aim to manage symptoms and improve the quality of life for patients.
Do Regenerative Medicine Therapies Provide Long-Term Relief in Chronic Low Back Pain: A Systematic Review and Metaanalysis.Differential patient responses to spinal manipulative therapy and their relation to spinal degeneration and post-treatment changes in disc diffusion.Cell therapy for the degenerating intervertebral disc.

Find a Location

Who is running the clinical trial?

Matthew PingreeLead Sponsor
Matthew Pingree, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
15 Total Patients Enrolled

Media Library

Angel® Concentrated Platelet Rich Plasma System (Platelet Rich Plasma) Clinical Trial Eligibility Overview. Trial Name: NCT05250947 — Phase 1
Lumbar Spondylosis Research Study Groups: PRP Injection Arm
Lumbar Spondylosis Clinical Trial 2023: Angel® Concentrated Platelet Rich Plasma System Highlights & Side Effects. Trial Name: NCT05250947 — Phase 1
Angel® Concentrated Platelet Rich Plasma System (Platelet Rich Plasma) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05250947 — Phase 1
Lumbar Spondylosis Patient Testimony for trial: Trial Name: NCT05250947 — Phase 1
~1 spots leftby Nov 2025